With a compound annual growth rate (CAGR) of 8%, the global dementia management market is projected to reach US$ 75.56 million by 2033 from US$ 35 million in 2023. The dementia management market expanded at a compound annual growth rate (CAGR) of 5% between 2018 and 2022.
According to the World Health Organization, in September 2022, around 55 million individuals worldwide had dementia, with more than 60% residing in low- and middle-income countries. As the proportion of the population over the age of 65 years rises in practically every country, this figure is predicted to climb to 78 million in 2030 and 139 million in 2050. Thus, the growing prevalence of dementia worldwide is expected to boost the market’s growth.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16641
The increasing prevalence of dementia and efforts by researchers to find a cure and improve brain health are also fueling the market growth. The market players are optimistic about the demand for dementia care products, backed by the growing emphasis on their usage.
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, government initiatives and increase in the number of research partnerships are boosting the market growth across North America. Europe is the second largest market for dementia care products, driven by its aging population and high disposable income. Asia Pacific is a growing market due to a shift towards point-of-care healthcare. The increasing number of hospitals in India and China presents a promising market opportunity globally.
Key Takeaways:
- From 2018 to 2022, the Dementia Management market grew at a CAGR of 5%.
- The global Dementia Management market is expected to grow with a 8% CAGR during 2023 to 2033.
- As of 2033, the Dementia Management Market is expected to reach US$ 75.56 Million
- According to the FMI analysis, Alzheimer accounts for the largest market share.
- North America is expected to possess 40% market share for the Dementia Management market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a share of 25% during the forecast period.
Request Customization:
https://www.futuremarketinsights.com/customization-available/rep-gb- 16641
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Dementia Management.” says an FMI analyst
Market Competition
Key players in the Dementia Management Market are Pfizer, Inc., Novartis AG, and Eli Lilly and Company, as well as healthcare providers and technology companies such as Teva Pharmaceutical Industries Ltd., GE Healthcare, and BrainScope among other global players.
- In April 2022, NovaMedica developed and registered an innovative combination of Donepezil and Memantine molecules, the primary therapies for dementia associated with Alzheimer’s disease. The drug is registered under the name MIOREOL. This is one of the combinations in the Russian market and the markets of the Eurasian Economic Union members and Europe.
- In March 2022, Corium, Inc. received United States FDA approval for ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of Alzheimer’s type.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Vascular Dementia Management market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Type, Therapy, Route of Administration, Distribution Channel, Drug class and Region
Key Segments:
Type:
- Alzheimer’s Disease Dementia
- Vascular Dementia
- Dementia With Lewy Bodies (Dlb)
- Parkinson’s Disease Dementia
- Frontotemporal Dementia
Drug Class:
- MAO Inhibitors
- Glutamate Inhibitors
- Cholinesterase Inhibitors
Therapy:
- Cognitive Stimulation Therapy
- Cognitive Behavioural Therapy
Route of Administration:
- Oral
- Parental
Distribution Channel:
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16641
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
